Figure 2.
Increase in antiviral T cells in PB of patients after receiving scheduled VSTs. (A) Absolute lymphocyte counts at infusion (pre) and 30 days after VST infusion (post) in all recipients. (B,C) Baseline (preinfusion) and peak (any point postinfusion) quantitated antiviral T cells as determined by interferon-γ ELISpot in recipients without any viremia and with viremia that cleared without intervention, respectively. (D) Representative examples of ELISpots from nontreatment failure patients with viremia that resolved with corresponding curves showing the kinetics of viremia.

Increase in antiviral T cells in PB of patients after receiving scheduled VSTs. (A) Absolute lymphocyte counts at infusion (pre) and 30 days after VST infusion (post) in all recipients. (B,C) Baseline (preinfusion) and peak (any point postinfusion) quantitated antiviral T cells as determined by interferon-γ ELISpot in recipients without any viremia and with viremia that cleared without intervention, respectively. (D) Representative examples of ELISpots from nontreatment failure patients with viremia that resolved with corresponding curves showing the kinetics of viremia.

Close Modal

or Create an Account

Close Modal
Close Modal